Step 1 topics → Reproductive → Testicular Cancer (Germ Cell and Non-Germ Cell)

Testicular Cancer (Germ Cell and Non-Germ Cell)

USMLE Step 1 trap: Incorrectly attributes AFP elevation to pure seminoma. Pure seminoma never produces AFP; an elevated AFP in a testicular mass means there is a nonseminomatous component regardless of histology.

Testicular cancer is the most common solid malignancy in young men (15–35), and USMLE Step 1 hammers it from multiple angles: pure pathology recognition, tumor marker interpretation, hormonal effects of non-germ cell tumors, and management logic. The germ cell tumors (seminoma vs. nonseminomatous subtypes) dominate the high-yield material, but Leydig and Sertoli cell tumors show up in vignettes designed to trap students who only memorized one direction of hormonal effect. The exam likes to give you a clinical scenario — painless testicular mass with specific lab values — and ask you to identify the tumor type or explain why a management step is or isn't appropriate.

The trickiest part is tumor markers. AFP and hCG are not interchangeable, and their presence or absence actively changes how you classify a tumor. Students consistently get burned by assuming AFP elevation is compatible with pure seminoma — it is not. If AFP is up, there is a nonseminomatous component, full stop, regardless of what the biopsy report says. USMLE Step 1 exploits exactly this gap. Similarly, hCG can be mildly elevated in seminoma (syncytiotrophoblastic giant cells), but AFP never is — that distinction is testable.

The non-germ cell tumors trip students because the hormonal effects aren't intuitive. Leydig cell tumors produce androgens, but in adult men that excess androgen gets aromatized peripherally to estrogen, causing gynecomastia — not the virilization you might expect. In prepubertal boys, the same tumor causes precocious puberty. The workup angle is also a favorite: transscrotal biopsy is contraindicated because it disrupts the lymphatic drainage pattern (scrotal skin drains to inguinal nodes, not the retroperitoneal nodes where testicular cancer metastasizes), and knowing why this matters is more likely to be tested than just knowing the rule.

From real student decks
68%have cards covering this topic
51%have mature cards

Common misconceptions

Common mistake
Wrong: AFP can be elevated in pure seminoma.
Right: Pure seminoma never produces AFP; an elevated AFP in a testicular mass means there is a nonseminomatous component regardless of histology.
Pure seminoma cells lack the machinery to synthesize AFP — they are not derived from yolk sac elements. If a patient has a testicular mass that looks like a seminoma on histology but AFP is elevated, the correct interpretation is that there is an occult nonseminomatous component (most likely yolk sac tumor elements) that the sampling missed. This matters clinically because the classification drives treatment, and it matters for Step 1 because the exam will test whether you trust the marker or trust the pathology report — always trust the AFP.
Common mistake
Wrong: A transscrotal biopsy is acceptable for diagnosing a testicular mass.
Right: Transscrotal biopsy is contraindicated because it risks seeding the inguinal lymphatics; the correct approach is radical orchiectomy via an inguinal incision.
The testis has a unique dual lymphatic drainage: testicular parenchyma drains to para-aortic retroperitoneal nodes, while the scrotal skin drains to inguinal nodes. If you violate the scrotum with a transscrotal biopsy, you risk seeding tumor into the inguinal lymphatics, fundamentally changing the metastatic pattern and complicating staging and treatment. Radical orchiectomy via an inguinal incision preserves the anatomically correct drainage pathway and is both diagnostic and therapeutic — the entire specimen is removed without scrotal disruption.
Common mistake
Wrong: Leydig cell tumors cause virilization in adults.
Right: Leydig cell tumors produce excess androgens causing precocious puberty in boys and gynecomastia (via peripheral estrogen conversion) in adults.
Leydig cell tumors produce excess androgens, but the end-organ effect in adult men is not virilization because adult men already have high baseline androgen levels. Instead, the excess androgens undergo peripheral aromatization to estrogens (primarily in adipose tissue), leading to gynecomastia. In prepubertal boys, however, the androgen excess causes precocious puberty with early virilization. The key is recognizing that the downstream hormonal effect depends on the developmental stage of the patient, not just what the tumor secretes.
Common mistake
Wrong: Nonseminomatous germ cell tumors are radiosensitive like seminomas.
Right: Seminomas are highly radiosensitive; nonseminomatous tumors are treated with chemotherapy (BEP) rather than radiation.
Seminomas are among the most radiosensitive solid tumors in the body, which is why low-stage seminomas are treated with radiation to the retroperitoneal lymph nodes. Nonseminomatous germ cell tumors (embryonal carcinoma, yolk sac tumor, choriocarcinoma, teratoma) do not share this property — they are relatively radioresistant and are instead treated with BEP chemotherapy (bleomycin, etoposide, cisplatin). If you apply radiation logic to a mixed or nonseminomatous tumor, you'll pick the wrong answer on Step 1 and undertreat in clinical practice.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Distinguish seminoma from nonseminomatous germ cell tumor subtypes (embryonal carcinoma, yolk sac tumor, choriocarcinoma, teratoma) based on histologic features, patient age, and clinical presentation.
  2. Assign the correct tumor markers — AFP, hCG, LDH — to each testicular tumor subtype, and use marker patterns to reclassify a tumor when histology and markers conflict (e.g., AFP elevation in an apparent 'pure seminoma').
  3. Predict the hormonal consequences of Leydig and Sertoli cell tumors in prepubertal boys versus adult men, including why excess androgen production leads to gynecomastia rather than virilization in adults.
  4. Explain why transscrotal biopsy is contraindicated for a suspected testicular mass and identify radical inguinal orchiectomy as the correct diagnostic and therapeutic approach, connecting this to lymphatic drainage anatomy.
  5. Differentiate the treatment approach for seminoma (radiosensitive, radiation ± chemotherapy) versus nonseminomatous tumors (BEP chemotherapy, not radiation) and apply this in management questions.

Can you avoid these mistakes?

A 24-year-old man has a painless testicular mass. Pathology shows large cells with clear cytoplasm and prominent nucleoli arranged in sheets with lymphocytic infiltrate — consistent with seminoma. His AFP comes back at 180 ng/mL (elevated). What is the correct interpretation of this result, and how does it change management?
A 6-year-old boy presents with early pubic hair development, enlarged phallus, and advanced bone age. Ultrasound shows a small unilateral testicular mass. What is the most likely tumor type, what does it secrete, and how would the presentation differ if the same tumor occurred in a 35-year-old man?
An attending asks an intern to perform a transscrotal biopsy on a 28-year-old with a solid testicular mass to confirm suspected testicular cancer before surgery. Why is this approach contraindicated, and what is the correct procedure? Be specific about the anatomical reason.
You are given two testicular cancer patients: one with pure seminoma stage I, one with embryonal carcinoma stage I. Both are post-orchiectomy. Outline how adjuvant treatment differs between these two patients and explain why the same approach cannot be used for both.

Related topics

Male Pelvic Anatomy (Testis, Ducts, Spermatic Cord) Cryptorchidism Gonadal Differentiation (SRY, MIS, Testosterone) Müllerian vs Wolffian Duct Derivatives 5α-Reductase Deficiency Complete Androgen Insensitivity Syndrome (CAIS)

See how your Anki deck covers this topic.

Upload your deck for a free audit →